Demant stock raises 2026 outlook after 15 percent H1 growth

Published on 09/29/2026 at 17:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Demant stock follows a 15 percent first-half revenue increase as EBIT before special items reached DKK 2.134 billion. Full-year EBIT guidance is DKK 4.4-4.8 billion.

Fotorealistische Szene einer Hörgeräte-Fertigung in modernem Reinraum, Medizintechnik-Industrie — Fotorealistisches Bild zeigt Demant A/S, ISIN DK0010268440, mit Hörgeräte-Fertigung und modernem Reinraum in Dänemark, Illustration mit AI erstellt.

Demant stock is backed by a stronger 2026 outlook after the hearing healthcare group reported 15 percent growth in the first half. The company also delivered DKK 2.134 billion in EBIT before special items and a 16.5 percent margin, according to Yahoo Finance in the August 12, 2026 earnings-call transcript.

Guidance moves higher

Management now expects organic revenue growth of 6-7 percent for fiscal year 2026 and EBIT before special items of DKK 4.4 billion-DKK 4.8 billion. The updated range compares with the company's earlier outlook and gives investors a clearer measure of the profit contribution expected from the second half.

The first-half growth mix was broad but acquisition-led. Organic growth contributed 7 percent, acquisitions added 10 percent, and foreign-exchange effects reduced reported growth by 3 percent, according to Yahoo Finance.

Oticon Zeal drives momentum

Demant said hearing aids gained momentum as the rollout of Oticon Zeal reached all channels and geographies. The product generated 10 percent growth in the hearing-aid business during the second quarter, while hearing care delivered 8 percent organic growth in the quarter.

The acquisition of KIND was another major growth factor. It contributed to a 31 percent local-currency increase in hearing care during the second quarter, with organic growth accounting for 8 percent, according to Yahoo Finance.

Analyst targets remain divided

Analyst views show a wide valuation debate. Oddo raised its price target from DKK 260 to DKK 275 while keeping a neutral rating, as MarketScreener reported on September 18, 2026. J.P. Morgan, meanwhile, listed Demant among its preferred European hearing-aid companies with an Overweight rating, according to Investing.com on September 9, 2026.

Demant stock keeps a wide range

Demant stock had a market capitalization of DKK 66.3 billion and a 52-week range of DKK 175.00 to DKK 321.20 as of September 29, 2026. The shares are listed on Nasdaq Copenhagen under ticker DEMANT.CO, while the company's operating profile centers on hearing aids, diagnostics, hearing implants and hearing care.